Cat. No. | Species | Product Description | Structure | Purity | Feature |
---|---|---|---|---|---|
ILB-H4110 | Human | Human IL-1 beta / IL-1F2 Protein, Tag Free (MALS verified) | ![]() |
![]() ![]() |
![]() ![]() ![]() ![]() |
Human IL-1 RII, Fc Tag (Cat. No. IL2-H4256) captured on CM5 chip via anti-human IgG Fc antibodies surface can bind Human IL-1 beta, Tag Free (Cat. No. ILB-H4110) with an affinity constant of 0.622 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
The purity of Human IL-1 beta, Tag Free (Cat. No. ILB-H4110) was more than 95% and the molecular weight of this protein is around 15-23 kDa verified by SEC-MALS.
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Canakinumab | ACZ-885,ACZ885 | Approved | Novartis | ILARIS | fda | Tumor necrosis factor receptor associated periodic syndrome, Cryopyrin-Associated Periodic Syndromes (CAPS), Systemic juvenile idiopathic arthritis, Hyperimmunoglobulin D syndrome, Familial mediterranean fever | NOVARTIS PHARMS | 2009-06-17 | Juvenile idiopathic arthritis (JIA), Tumor necrosis factor receptor associated periodic syndrome, Cryopyrin-Associated Periodic Syndromes (CAPS), Systemic juvenile idiopathic arthritis, Hyperimmunoglobulin D syndrome, Arthritis, Familial mediterranean fever | Details |
Rilonacept | KPL-914; RGN-303 | Approved | Regeneron Pharmaceutical, kiniksa pharmaceuticals | ARCALYST | fda | Muckle-Wells Syndrome (MWS), Familial chylomicronemia syndrome (FCS), Cryopyrin-Associated Periodic Syndromes (CAPS) | REGENERON PHARMACEUTICALS | 2008-02-27 | Cardiovascular disorders, Familial chylomicronemia syndrome (FCS), Muckle-Wells Syndrome (MWS), Urticaria, Cryopyrin-Associated Periodic Syndromes (CAPS) | Details |
PG-201 | PG-201,PG 201 | Approved | ViroMed, PMG Pharm | Osteoarthritis (OA) | Details | |||||
Diacerein | AC-201; AC-203; KW-4800; SF-277; AC-201CR; CCP-020; Art-50 | Approved | Unknown | Diacerein Capsules | cfda | Osteoarthritis (OA) | 2015-03-15 | Osteoarthritis (OA) | Details | |
Thalidomide | NSC-527179; NSC-66847; K-17,NSC527179; NSC66847; K17,NSC 527179; NSC 66847; K 17 | Approved | Celgene | THALOMID | fda | Erythema nodosum leprosum (ENL), Multiple myeloma (MM) | CELGENE | 1998-07-16 | Erythema nodosum leprosum (ENL), Multiple myeloma (MM) | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Aceclofenac/Diacerein/Glucosamine | Phase Ⅲ | Jenburkt Pharmaceuticals | Osteoarthritis (OA) | Details | |
Interleukin-1 receptor (Immunex) | Phase Ⅱ | Amgen | Myeloid leukemia, Type 1 diabetes, HIV infection, Graft versus host disease, Transplant rejection, Hypersensitivity | Details | |
HMPL-004 (Hutchison Medipharma) | HMPL-004 | Phase Ⅲ | Hutchison Medipharma | Ulcerative colitis, Crohn's disease | Details |
MRX-1 | MRX-1,MRX 1,MRX1 | Phase Ⅰ | Akari | Atopic dermatitis | Details |
CYT 013 IL1bQb | Phase Ⅱ | Kuros Biosciences | Type 2 diabetes | Details | |
Aceclofenac/Diacerein | Phase Not Specified | Cadila Healthcare | Osteoarthritis (OA) | Details | |
IL-1 Affibody | Preclinical | Affibody, SOBI | Autoimmune diseases, Inflammation | Details | |
APX-002 (Apexigen/Jiangsu T-mab BioPharma) | APX-002; TK-002 | Preclinical | Epitomics, Apexigen, Jiangsu T-mab BioPharma | Inflammation | Details |
Binetrakin | Sch-39400 | Phase Ⅱ | Merck Sharp & Dohme, Nonindustrial source | Non small cell lung cancer (NSCLC), Gastrointestinal cancer, Solid tumours, Inflammation, Acute lymphoblastic leukaemia (ALL), Rheumatoid arthritis (RA), Immunodeficiency disorders | Details |
CC-11006 | CC-11006 | Phase Ⅰ | Celgene | Myelodysplastic syndrome (MDS), Inflammation | Details |
Ajulemic acid | CPL-7075; CT-3; DMH-THC-11-OIC; DMH-11C; HU-239; IP-751; JBT-101 | Phase Ⅲ | Corbus Pharma | Cystic fibrosis (CF), Systemic lupus erythematosus, Dermatomyositis, Systemic sclerosis | Details |
lutikizumab | ABT-981 | Phase Ⅱ | Abbvie | Osteoarthritis (OA) | Details |
CDP-484 | CDP-484 | Phase Ⅱ | UCB, Nektar | Rheumatoid arthritis (RA) | Details |
RPH-104 | RPH-104 | Phase Ⅲ | TRPHARM | Coronavirus Disease 2019 (COVID-19) | Details |
KOB-03 | KOB-03 | Phase Ⅱ | Dong Wha Pharmaceuticals | Allergic rhinitis (AR) | Details |
金纳单抗 | Phase Ⅰ | GeneScience Pharmaceutical (GenSci) | Acute gouty arthritis (GA), Systemic juvenile idiopathic arthritis | Details | |
Gevokizumab | AB-7; S-78989; XMA-005.2; XOMA-052; VPM-087 | Phase Ⅲ | Xoma, Novartis | Uveitis | Details |
LY 2189102 | LY-2189102 | Phase Ⅱ | Lilly | Cardiovascular disorders, Type 2 diabetes, Rheumatoid arthritis (RA) | Details |
Mobenakin | OCT-43 | BLA Filing | Nonindustrial source, Otsuka, Chiron | Urogenital cancer, Glioma, Lymphoma, Cancer | Details |
PXL-01 | PXL-01 | Phase Ⅲ | ProMore Pharma, Technomark Life Sciences, PharmaResearch Products | Post-surgical adhesions | Details |
This web search service is supported by Google Inc.